Aurobindo Pharma has expanded its partnership further by executing licensing and supply agreements for several solid dosage and sterile products with Pfizer Inc. The agreement allows access to Pfizer?s newly-formed established product business unit to exploit the sales potential for these post loss of exclusivity (LOE) products through its global commercial presence. Aurobindo has a large manufacturing base approved by several regulatory authorities with strong product portfolio for the manufacture of post LOE products.
The partnership alliance is mutually beneficial, said a release. ?We initiated our partnership with a few products. The execution of these agreements will pave the way for further strengthening our partnership and will accelerate Pfizer?s strategy for expanding our established products portfolio,? said David Simmons, president and general manager, Pfizer established product business unit (EPBU).
?We look forward to working with Aurobindo and are delighted that they are able to contribute towards our strategy both on solids, steriles and product reformulations,? said Kelvin Cooper, senior vice-president, portfolio devolvement, EPBU.
Commenting on the alliance, PV Ramprasad Reddy, chairman, Aurobindo Pharma said the current agreements are targeted towards the US and European markets and will continue to explore ways to further extend this partnership. Aurobindo Pharma Ltd manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company?s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company?s robust product portfolio is spread over six major therapeutic/product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals, and anti-allergics, supported by an outstanding R&D set-up.